Gerard M.J. Bos

Hyperhomocysteinemia as a Risk Factor for Deep-Vein Thrombosis

Martin den Heijer, Ted Koster, Henk J. Blom et al. · New England Journal of Medicine · 1996 · 1.1K citations · Full text

Medicine, Hematology, Clinical Biochemistry +11

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

Pieter Sonneveld, Ingo Schmidt‐Wolf, Bronno van der Holt et al. · Journal of Clinical Oncology · 2012 · 826 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç et al. · The Lancet Haematology · 2020 · 384 citations · Full text

Medicine, Hematology, Oncology +17

Hyperhomocysteinemia and Venous Thrombosis: A Meta-analysis

Martin den Heijer, Frits Rosendaal, Henk J. Blom et al. · Thrombosis and Haemostasis · 1998 · 379 citations

Medicine, Hematology, Clinical Epidemiology +11

Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?

Martin den Heijer, W.B.J. Gerrits, H. L. Haak et al. · The Lancet · 1995 · 372 citations

Medicine, Hematology, Internal Medicine +13